AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03814200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475
Description: Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
Study NCT03814200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
Study NCT03169426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta Blockers Carvedilol Phosphate
Description: Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
Study NCT02998723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Booster Teaching
Description: The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
Study NCT02998723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Booster Teaching
Description: The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
Study NCT01417845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise Training
Description: * High intensity resistance and aerobic training~* Resistance training is performed 2 days per week for 3 months~* Aerobic training is performed on the same days as resistance training and 1 additional day per week.
Study NCT01417845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Exercise Training
Description: * Moderate intensity resistance and aerobic training~* Resistance training is performed on 2 days per week for 3 months.~* Aerobic training is performed on the same days as resistance training and 1 additional day per week.
Study NCT00939692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study NCT00939692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study NCT03648632 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 250 ng/kg
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
Study NCT01466829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid hormone
Description: 100 microgram daily. S.c
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 escalating doses,1200 ng/kg D15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
Study NCT03983395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 at the MTD and/or RP2D dose
Description: ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
Study NCT01385735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
Study NCT01385735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 Tbl per day, 12 week (84 days) duration
Study NCT02516670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study NCT02516670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02516670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02516670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03942432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Blood samples at T0, T30min, T120min
Study NCT01466829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; saline injection.
Study NCT00692536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NNR (Nordic Nutrition Recommendations)
Description: Diet with equal amounts of fat, protein and carbohydrates
Study NCT04281485 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: PF-06939926
Description: PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
Study NCT04281485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
Study NCT00692536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MPD (Modified paleolithic diet)
Description: A diet high in protein and fat, but low in carbohydrates
Study NCT01450852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
Study NCT03942432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: weight, length, waist measurement, cardiac frequency, blood pressure
Study NCT03942432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
Study NCT03942432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 Tesla abdominal MRI
Study NCT03942432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Measurement of body composition
Study NCT03942432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life, physical activity, alcohol consumption and eating habits
Study NCT03417271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
Study NCT01150084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16-week lunchtime walking intervention
Description: 10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
Study NCT01150084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: delayed treatment
Description: to start at week 10
Study NCT01583179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: added to nerve block, 0.3mg one time peripheral block use
Study NCT01718184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: toric intraocular lens implantation
Description: piggyback Sulcolflex toric intraocular lens implantation
Study NCT01718184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sulcoflex intraocular lens implantation
Study NCT04281485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
Study NCT04281485 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: PF-06939926
Description: PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
Study NCT00264004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: 30 mg \& 45 mg oral tablet
Study NCT03085719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
Study NCT03085719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation is used to shrink the cancer
Study NCT03881098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopies
Description: Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested.
Study NCT03881098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sputum Sample
Description: Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
Study NCT03881098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
Study NCT00898222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 81 mg orally daily for two weeks
Study NCT01528787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.01%
Description: Administered to study eye, once daily (QD) in the morning (AM) for 7 days
Study NCT01528787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to study eye, QD AM for 7 days
Study NCT01528787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.04%
Description: Administered to study eye, QD AM for 7 days
Study NCT01528787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AR-13324 Ophthalmic Solution Vehicle
Description: Administered to study eye, QD AM for 7 days
Study NCT04047901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Patients undergo 16 weeks of physical training
Study NCT03592160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
Study NCT02700178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
Study NCT04259853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Revascularization on non culprit vessel
Study NCT04259853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Revascularization on non culprit vessel
Study NCT00372879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 800IU bid
Study NCT01356004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: live attenuated chicken pox vaccine
Description: Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
Study NCT01356004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline, efficacy
Description: 4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
Study NCT02697942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: The investigators will provide participants with tablets to play brain games through Lumosity.
Study NCT02697942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: The investigators will provide participants with foot peddlers.
Study NCT04627909 — intervention group
Intervention type: OTHER
Intervention: Robot
Description: The patient interacts with a robot
Study NCT03438370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three monthly ART supply at CAGs
Description: Sites where three monthly ART supply will be provided at outreaches
Study NCT03438370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six monthly ART supply at outreaches
Description: Sites where six monthly ART will supply will be provided at outreaches
Study NCT00983008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protected time and Dedicated time
Description: On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
Study NCT04627909 — intervention group
Intervention type: OTHER
Intervention: Medical Personnel
Description: The patient interacts with medical personnel
Study NCT04627909 — intervention group
Intervention type: OTHER
Intervention: Caregiver
Description: The patient interacts with the caregiver
Study NCT04019366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
Study NCT04019366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
Study NCT02274337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: patients take avitinib orally once per day at different dose
Study NCT00602355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care.
Study NCT03473223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I [human] (apoA-I)
Description: Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration
Study NCT03473223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25% albumin solution diluted to 4.4%
Study NCT06628843 — intervention group
Intervention type: OTHER
Intervention: cesarean section rate
Description: Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
Study NCT03539822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: by mouth
Study NCT03539822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: infusion
Study NCT03539822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: infusion
Study NCT02839161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel
Study NCT02839161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel
Study NCT02839161 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Study NCT00602355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline.
Study NCT00602355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Description: IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
Study NCT00602355 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical management
Description: Clinical management includes treatment as usual for those receiving medication for depression.
Study NCT00602355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical management
Description: Clinical management includes treatment as usual for those receiving medication for depression.
Study NCT00602355 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mothercrafting
Description: Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care